| Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing JC Reader, TP Matthews, S Klair, KMJ Cheung, J Scanlon, N Proisy, ... Journal of medicinal chemistry 54 (24), 8328-8342, 2011 | 76 | 2011 |
| Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements JM Large, JE Torr, FI Raynaud, PA Clarke, A Hayes, F di Stefano, F Urban, ... Bioorganic & medicinal chemistry 19 (2), 836-851, 2011 | 26 | 2011 |
| On the nucleophilic tele-substitution of dichloropyrazines by metallated dithianes JE Torr, JM Large, PN Horton, MB Hursthouse, E McDonald Tetrahedron letters 47 (1), 31-34, 2006 | 20 | 2006 |
| Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use I Collins, JC Reader, TP Matthews, KM Cheung, N Proisy, DH Williams, ... US Patent 8,058,045, 2011 | 18 | 2011 |
| Discovery of clinical candidate NT-0796, a brain-penetrant and highly potent NLRP3 inflammasome inhibitor for neuroinflammatory disorders D Harrison, A Billinton, MG Bock, JR Doedens, CA Gabel, MK Holloway, ... Journal of Medicinal Chemistry 66 (21), 14897-14911, 2023 | 17 | 2023 |
| Discovery and optimization of triazolopyrimidinone derivatives as selective NLRP3 inflammasome inhibitors D Harrison, MG Bock, JR Doedens, CA Gabel, MK Holloway, A Lewis, ... ACS medicinal chemistry letters 13 (8), 1321-1328, 2022 | 15 | 2022 |
| Bicyclylaryl-aryl-amine compounds and their use I Collins, JC Reader, DH Williams, SS Klair, JE Scanlon, N Piton, ... US Patent 8,530,468, 2013 | 13 | 2013 |
| Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use I Collins, JC Reader, TP Matthews, KM Cheung, N Proisy, DH Williams, ... US Patent 8,367,658, 2013 | 12 | 2013 |
| 9H-pyrimido [4, 5-B] indoles, 9H-pyrido [4', 3': 4, 5] pyrrolo [2, 3-D] pyridines, and 9H 1, 3, 6, 9 tetraaza-fluorenes as CHK1 kinase function inhibitors I Collins, JC Reader, S Klair, J Scanlon, G Addison, M Cherry US Patent 8,618,121, 2013 | 10 | 2013 |
| Identification and structure-guided optimization of novel inhibitors of Checkpoint kinase 1 (Chk1) through combined biochemical and crystallographic screening J Reader, D Williams, S Klair, M Cherry, M Fisher, J Scanlon, N Piton, ... Cancer Research 68 (9_Supplement), 757-757, 2008 | 8 | 2008 |
| A convenient one-pot preparation and applications of high loading benzhydrylamine solid phase linkers JE Torr, JM Large, E McDonald Tetrahedron letters 48 (11), 1951-1954, 2007 | 6 | 2007 |
| Pyrimidine derivatives as mTOR inhibitors R Lynch, AD Cansfield, HS Niblock, D Hardy, JE Scanlon, R Adrego, ... US Patent 8,785,457, 2014 | 4 | 2014 |
| Pyrimidine derivatives as mtor inhibitors R Lynch, AD Cansfield, HS Niblock, D Hardy, JE Scanlon, R Adrego, ... US Patent App. 14/304,375, 2014 | 3 | 2014 |
| Heterocyclyl pyrimidine analogues as jak inhibitors J Freeman, V Reader, G Addison, N Ramsden, JE Scanlon, RJ Harrison | 3 | 2014 |
| Dihydropyrrolo pyrimidine derivatives as mtor inhibitors R Lynch, AD Cansfield, DP Hardy, JE Scanlon, R Adrego | 3 | 2012 |
| Design and Combinatorial Synthesis of a Library of Methylenesulfonamides and Related Compounds as Potential Kinase Inhibitors JE Torr, JM Large, E McDonald Combinatorial Chemistry & High Throughput Screening 12 (3), 275-284, 2009 | 3 | 2009 |
| Sulfonylurea derivatives and uses thereof MG Bock, D Harrison, JE Scanlon US Patent App. 17/618,188, 2023 | 2 | 2023 |
| Sulfonamide derivatives and uses thereof MG Bock, D Harrison, JE Scanlon US Patent App. 17/618,173, 2022 | 2 | 2022 |
| Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof MG Bock, D Harrison, JE Scanlon US Patent App. 18/043,883, 2024 | 1 | 2024 |
| Heterocyclyl pyrimidine analogues as jak inhibitors J Freeman, V Reader, G Addison, N Ramsden, JE Scanlon, RJ Harrison | 1 | 2013 |
